Literature DB >> 21108015

A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations.

Ashwin N Ananthakrishnan1, Emily L McGinley, David G Binion, Kia Saeian.   

Abstract

INTRODUCTION: The past decade has seen a change in inflammatory bowel disease (IBD; Crohn's disease (CD) and ulcerative colitis (UC)) treatment, with increasing use of immunomodulators and biologics. The impact of this on IBD hospitalization outcomes is unknown.
METHODS: We identified hospitalizations with a diagnosis of IBD using data from the Nationwide Inpatient Sample, a national US discharge database. We compared the proportion of hospitalizations resulting in surgery in the entire cohort and within each disease severity stratum for the years 1998, 2004, and 2007.
RESULTS: There were an estimated 89,673 hospitalizations for CD in 1998 increasing to 150,593 hospitalizations in 2007. UC hospitalizations increased from 56,911 in 1998 to 86,611 in 2007. This increase was primarily among low or intermediate severity hospitalizations not requiring surgery. For CD, the proportion of bowel surgeries during hospitalization decreased from 17.3% in 1998 to 12.4% in 2007 (p < 0.001) while for UC, the proportion of colectomy decreased from 9.5% in 1998 to 6.2% in 2007 (p < 0.001). For both diagnoses, this reduction was significant in those with a low severity of disease but not with in those with the highest severity stratum.
CONCLUSIONS: There continues to be an increase in the number of hospitalizations in patients with IBD. The numbers of non-elective bowel surgeries among those with the highest severity of disease continues to increase suggesting need for further research into improving outcomes in this cohort at high risk for adverse outcome.

Entities:  

Mesh:

Year:  2010        PMID: 21108015     DOI: 10.1007/s11605-010-1396-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  30 in total

1.  Infliximab for hospitalized patients with severe ulcerative colitis.

Authors:  Miguel Regueiro; Jennifer Curtis; Scott Plevy
Journal:  J Clin Gastroenterol       Date:  2006-07       Impact factor: 3.062

2.  Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.

Authors:  Tine Jess; Lene Riis; Ida Vind; Karen Vanessa Winther; Sixten Borg; Vibeke Binder; Ebbe Langholz; Ole Østergaard Thomsen; Pia Munkholm
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

3.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

4.  Trends in hospitalization rates for inflammatory bowel disease in the United States.

Authors:  Meenakshi Bewtra; Chinyu Su; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03-26       Impact factor: 11.382

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Infliximab decreases resource use among patients with Crohn's disease.

Authors:  Joel H Rubenstein; Rachel Y Chong; Russell D Cohen
Journal:  J Clin Gastroenterol       Date:  2002-08       Impact factor: 3.062

7.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

8.  Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume.

Authors:  Ashwin N Ananthakrishnan; Emily L McGinley; David G Binion
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

9.  Colectomy rate in acute severe ulcerative colitis in the infliximab era.

Authors:  A Aratari; C Papi; V Clemente; A Moretti; R Luchetti; M Koch; L Capurso; R Caprilli
Journal:  Dig Liver Dis       Date:  2008-05-09       Impact factor: 4.088

10.  Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.

Authors:  Jaya Punati; James Markowitz; Trudy Lerer; Jeffrey Hyams; Subra Kugathasan; Anne Griffiths; Anthony Otley; Joel Rosh; Marian Pfefferkorn; David Mack; Jonathan Evans; Athos Bousvaros; M Susan Moyer; Robert Wyllie; Maria Oliva-Hemker; Adam Mezoff; Neal Leleiko; David Keljo; Wallace Crandall
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

View more
  23 in total

1.  Infliximab or ciclosporin for acute severe ulcerative colitis?

Authors:  Ashwin N Ananthakrishnan
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-06-21

2.  Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis.

Authors:  S Sebastian; S Myers; S Nadir; S Subramanian
Journal:  Dig Dis Sci       Date:  2018-12-07       Impact factor: 3.199

Review 3.  Surgical strategies in paediatric inflammatory bowel disease.

Authors:  Colin T Baillie; Jennifer A Smith
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

4.  Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach.

Authors:  Ashwin N Ananthakrishnan; Tianxi Cai; Guergana Savova; Su-Chun Cheng; Pei Chen; Raul Guzman Perez; Vivian S Gainer; Shawn N Murphy; Peter Szolovits; Zongqi Xia; Stanley Shaw; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Robert M Plenge; Katherine P Liao
Journal:  Inflamm Bowel Dis       Date:  2013-06       Impact factor: 5.325

Review 5.  Perioperative Considerations in Crohn Disease and Ulcerative Colitis.

Authors:  T Paul Nickerson; Amit Merchea
Journal:  Clin Colon Rectal Surg       Date:  2016-06

6.  Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.

Authors:  K T Park; Aaron Sin; May Wu; Dorsey Bass; Jay Bhattacharya
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

7.  Early surgery in Crohn's disease a benefit in selected cases.

Authors:  Vinna An; Lauren Cohen; Matthew Lawrence; Michelle Thomas; Jane Andrews; James Moore
Journal:  World J Gastrointest Surg       Date:  2016-07-27

Review 8.  Strategies for the care of adults hospitalized for active ulcerative colitis.

Authors:  Suresh Pola; Derek Patel; Sonia Ramamoorthy; Elisabeth McLemore; Marianne Fahmy; Jesus Rivera-Nieves; John T Chang; Elisabeth Evans; Michael Docherty; Mark Talamini; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-24       Impact factor: 11.382

9.  Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.

Authors:  Colleen R Kelly; Chioma Ihunnah; Monika Fischer; Alexander Khoruts; Christina Surawicz; Anita Afzali; Olga Aroniadis; Amy Barto; Thomas Borody; Andrea Giovanelli; Shelley Gordon; Michael Gluck; Elizabeth L Hohmann; Dina Kao; John Y Kao; Daniel P McQuillen; Mark Mellow; Kevin M Rank; Krishna Rao; Arnab Ray; Margot A Schwartz; Namita Singh; Neil Stollman; David L Suskind; Stephen M Vindigni; Ilan Youngster; Lawrence Brandt
Journal:  Am J Gastroenterol       Date:  2014-06-03       Impact factor: 10.864

10.  Thrombin mediates vagal apoptosis and dysfunction in inflammatory bowel disease.

Authors:  Danielle Fritze; Weizhen Zhang; Ji-Yao Li; Biaoxin Chai; Michael Mulholland
Journal:  J Gastrointest Surg       Date:  2014-06-11       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.